» Articles » PMID: 25866483

Thrombosis in Inflammatory Bowel Diseases: What's the Link?

Overview
Journal Thromb J
Publisher Biomed Central
Date 2015 Apr 14
PMID 25866483
Citations 55
Authors
Affiliations
Soon will be listed here.
Abstract

Inflammatory bowel disease affects more than 2 million people in Europe, with almost 20% of patients being diagnosed in pediatric age. Patients with inflammatory bowel disease are at increased risk of thromboembolic complications which may affect patients' morbidity and mortality. The risk of the most common thromboembolic events, such as deep venous thrombosis and pulmonary embolism, are estimated to be three-fold increased compared to controls, but many other districts can be affected. Moreover, patients with ulcerative colitis and Crohn's disease experience thromboembolic events at a younger age compared to general population. Many factors have been investigated as determinants of the pro-thrombotic tendency such as acquired risk factors or genetic and immune abnormalities, but a unique cause has not been found. Many efforts have been focused on the study of abnormalities in the coagulation cascade, its natural inhibitors and the fibrinolytic system components and both quantitative and qualitative alterations have been demonstrated. Recently the role of platelets and microvascular endothelium has been reviewed, as the possible link between the inflammatory and hemostatic process.

Citing Articles

Neutrophils: From Inflammatory Bowel Disease to Colitis-Associated Colorectal Cancer.

Chen T, Liu J, Hang R, Chen Q, Wang D J Inflamm Res. 2025; 18:925-947.

PMID: 39871958 PMC: 11770381. DOI: 10.2147/JIR.S497701.


Platelet Count at Diagnosis Is Associated with Endoscopic Activity in Pediatric Patients with Crohn's Disease.

Lee S Pediatr Gastroenterol Hepatol Nutr. 2025; 28(1):46-53.

PMID: 39839470 PMC: 11745566. DOI: 10.5223/pghn.2025.28.1.46.


Uncovering novel therapeutic clues for hypercoagulable active ulcerative colitis: novel findings from old data.

Yu Z, Zhao D, Zhang Y, Shen K, Shao S, Chen X Gastroenterol Rep (Oxf). 2024; 12:goae105.

PMID: 39735422 PMC: 11681937. DOI: 10.1093/gastro/goae105.


Pulmonary Manifestations of IBD: Case Report and Review of the Literature.

Herling A, Perluk T, Freund O, Maharshak N, Cohen N J Clin Med. 2024; 13(18).

PMID: 39336887 PMC: 11432544. DOI: 10.3390/jcm13185401.


The emerging role of neutrophil extracellular traps in ulcerative colitis.

Long D, Mao C, Xu Y, Zhu Y Front Immunol. 2024; 15:1425251.

PMID: 39170617 PMC: 11335521. DOI: 10.3389/fimmu.2024.1425251.


References
1.
Owczarek D, Undas A, Foley J, Nesheim M, Jablonski K, Mach T . Activated thrombin activatable fibrinolysis inhibitor (TAFIa) is associated with inflammatory markers in inflammatory bowel diseases TAFIa level in patients with IBD. J Crohns Colitis. 2012; 6(1):13-20. DOI: 10.1016/j.crohns.2011.06.005. View

2.
Grip O, Svensson P, Lindgren S . Inflammatory bowel disease promotes venous thrombosis earlier in life. Scand J Gastroenterol. 2000; 35(6):619-23. DOI: 10.1080/003655200750023589. View

3.
Chamouard P, Grunebaum L, Wiesel M, Frey P, Wittersheim C, Sapin R . Prothrombin fragment 1 + 2 and thrombin-antithrombin III complex as markers of activation of blood coagulation in inflammatory bowel diseases. Eur J Gastroenterol Hepatol. 1995; 7(12):1183-8. DOI: 10.1097/00042737-199512000-00010. View

4.
Miehsler W, Reinisch W, Valic E, Osterode W, Tillinger W, Feichtenschlager T . Is inflammatory bowel disease an independent and disease specific risk factor for thromboembolism?. Gut. 2004; 53(4):542-8. PMC: 1773996. DOI: 10.1136/gut.2003.025411. View

5.
Yuhara H, Steinmaus C, Corley D, Koike J, Igarashi M, Suzuki T . Meta-analysis: the risk of venous thromboembolism in patients with inflammatory bowel disease. Aliment Pharmacol Ther. 2013; 37(10):953-62. DOI: 10.1111/apt.12294. View